ALT BioScience™ has a discovery method for photoinserting compounds into specific sites on antibodies without loss of antigen recognition. Also published in the PNAS, the process is successful in incorporating radioactivity, biotin, anticancer drugs and other small compounds of importance into antibodies. This technology has the ability to rapidly produce antibodies that are more sensitive for diagnostic procedures and for therapeutic uses such as cancer cell specific antibodies, which contain high levels of the radioactive species 32 P and 33 P phosphate. The cancer cell derived antibodies containing these radioactive species are widely believed to be one of the best developments for treating solid tumors.

Co-development opportunities exist for the development of an active laboratory for optimization or modification of antibodies for use in diagnosis and therapeutic treatments. Others have reported the production of "Super Antibodies" using ALT BioScience's™ technology that involves photo-insertion of a small peptide that allows internalization of the antibody that is directed toward an intracellular protein involved in growth and is specific for cancer cells. ALT BioScience™ currently has the technology to readily test and modify other antibodies for multiple approaches, including internalization.